EMA CHMP adopts positive opinion recommending authorisation of Moderna's COVID-19 mRNA vaccine targeting the SARS-CoV-2 variant LP.8.1

25 July 2025 - Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European ...

Read more →

Pfizer and BioNTech receive positive CHMP opinion for LP.8.1 adapted COVID-19 vaccine in the European Union

25 July 2025 - Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sub-lineages ...

Read more →

Moderna receives US FDA approval for COVID-19 vaccine mNEXSPIKE

31 May 2025 - mNEXSPIKE becomes Moderna's third FDA approved product. ...

Read more →

Pfizer and BioNTech submit EMA application for COVID-19 vaccine targeting LP.8.1 for 2025-2026 season

28 May 2025 -  2025 -- Pfizer and BioNTech today announced that they have submitted a regulatory application to the ...

Read more →

Moderna files FDA application for the LP.8.1 targeting COVID-19 vaccine

23 May 2025 - Moderna today announced that it has submitted an application to the US FDA for review of its ...

Read more →

US FDA approves BLA for Novavax's COVID-19 vaccine

19 May 2025 - Nuvaxovid is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the US. ...

Read more →

Update on US FDA BLA for Novavax’s COVID-19 vaccine

2 April 2025 - Novavax can confirm that 1 April 2025, was the US FDA’s Prescription Drug User Fee Act date ...

Read more →

European Commission approves CSL and Arcturus Therapeutics’ Kostaive, the first self-amplifying mRNA COVID-19 vaccine

14 February 2025 - Kostaive represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to ...

Read more →

How the Morrison Government passed over an Australian company for a US pharmaceutical giant

13 November 2024 - Australia’s audit office will probe the Morrison Government’s $2 billion deal with US pharmaceutical giant Moderna ...

Read more →

Novavax's updated 2024-2025 Nuvaxovid COVID-19 vaccine receives authorisation in the EU

9 October 2024 - Novavax today announced that the European Commission granted marketing authorisation for Novavax's updated 2024-2025 Nuvaxovid COVID-19 vaccine ...

Read more →

Pfizer Canada and BioNTech receive Health Canada approval of Omicron KP.2 variant adapted COVID-19 vaccine

24 September 2024 - Omicron KP.2 variant adapted vaccine Comirnaty is now authorised in Canada for individuals 6 months of age ...

Read more →

New COVID-19 vaccine by Moderna approved by Health Canada

17 September 2024 - Health Canada has approved an updated version of Moderna’s COVID-19 vaccine, a decision that means some ...

Read more →

EMA Committee for Medicinal Products for Human Use adopts positive opinion recommending authorisation of Moderna's COVID-19 mRNA vaccine targeting the SARS-COV-2 variant JN.1

5 September 2024 - Moderna's updated COVID-19 mRNA vaccine will be available for the 2024-2025 vaccination season, pending a European ...

Read more →

FDA authorises updated Novavax COVID-19 vaccine to better protect against currently circulating variants

30 August 2024 - Today, the US FDA granted emergency use authorisation for an updated version of the Novavax COVID-19 vaccine ...

Read more →

FDA approves and authorises updated mRNA COVID-19 vaccines to better protect against currently circulating variants

22 August 2024 - Today, the US FDA approved and granted emergency use authorisation for updated mRNA COVID-19 vaccines (2024-2025 formula) ...

Read more →